The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins

American Journal of Medicine

Volumn 105, Issue 1 B, 1998, Pages 8S-12S

  Bjorkman, David J ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

EID: 0032572519     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00069-2     Document Type: Conference Paper

References (31)

1. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115: 787-796.
2. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke. 1990;21:IV12-IV23.
3. Piper JP, Vane JR. Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature. 1969;223:29-35.
4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231:232-235.
5. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971;231: 235-237.
6. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995;15:179-194.
7. 2 synthase-1. Nature. 1994;367:243-249.
8. Wallace JL. Prostaglandins, NSAIDs and cytoprotection. Gastroenterol Clin North Am. 1992;21:631-641.
9. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44:1-10.
10. Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem. 1976;251:2629-2636.
11. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-src.-inducible gene. Proc Natl Acad Sci USA. 1989;86:1178-1182.
12. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270: G393-G400.
13. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
14. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995;270:10902-10908.
15. O'Banion MK, Winn VD, Yound DE. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA. 1992;89: 4888-4892.
16. Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem. 1994;269:21322-21329.
17. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
18. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer non-steroidal anti-inflammatory drugs. Am J Med. 1993;95(suppl 2A):40S-44S.
19. Laneuville O, Breuer KD, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927-934.
20. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996;25:279-298.
21. Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 1995;281:107-111.
22. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol. 1993;88:1318-1323.
23. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
24. Taha AS, McLaughlin S, Sturrock RD, Russell RI. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol. 1989;28:329-332.
25. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995;42:428-433.
26. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
27. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83:473-482.
28. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409.
29. Huskisson EC, Ghozlan R, Kurthen R, et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol. 1996;35:29-34.
30. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997;112:1000-1016.
31. DuBois R, Eberhart CE, Williams CS. Introduction to eicosanoids and the gastroenteric tract. Gastroenterol Clin North Am. 1996;25:267-277.